不错不错，A 股的 ADC 板块基本都远离海平面了。于是就布局了人气不高，国内率先布局 PD-1 靶向 ADC 的$乐普生物-B.HK 。
但乐普此前如平湖一般的表现，让我以为这次只能是长期持有了，但没想到没多长时间就收获超 10 个点了。原本商业化没开始的时候还能保证横盘，商业化后减亏了反而重心还下移，果然是打压吸筹的套路！
本来制约乐普的是流动性，现在纳入了 MSCI 等几大指数，流动性问题也会稍微缓解一些了！
Posts
Likes ReceivedThe copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Like